sandoz

The company was founded in 1886 by Alfred Kern (1850–1893) and Edouard Sandoz (1853–1928) in Basel (Switzerland) under the name Chemiefirma Kern und Sandoz. Initially the company focused on production of dyes namely alizarin blue and auramine. When Kern died, the company changed its name to Chemische Fabrik vormals Sandoz in 1895 and began producing pharmaceuticals for the first time the same year. As early as 1895, the first pharmaceutical substance called antipyrine was produced to reduce fever. In 1899 they started producing saccharin.{{Cite book |last=Sandoz |first=Chemische Fabrik Vormals |url=https://books.google.com/books?id=PHJ0zQEACAAJ |title=Viscowalkfarbstoffe |date=1938 |publisher=Sandoz |language=de |access-date=2023-07-19 |archive-date=2023-10-04 |archive-url=https://web.archive.org/web/20231004050617/https://books.google.com/books?id=PHJ0zQEACAAJ |url-status=live }}

In 1917, Sandoz entered pharmaceutical research when Arthur Stoll (1887–1971) was hired, and, in 1929, Calcium Sandoz was introduced, laying the foundation research into modern calcium therapy.{{Cite web |title=Live. Magazine |url=https://live.novartis.com/article/sandoz-through-the-years/intro |access-date=2023-07-05 |website=live.novartis.com |language=en-us |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705072351/https://live.novartis.com/article/sandoz-through-the-years/intro |url-status=live }}{{Cite web |date=2010-12-15 |title=Company history |url=http://www.novartis.com/about-novartis/company-history/index.shtml |url-status=dead |archive-url=https://web.archive.org/web/20101230203847/http://www.novartis.com/about-novartis/company-history/index.shtml |archive-date=30 December 2010 |access-date=2012-01-16 |publisher=Novartis.com |df=dmy}}

In 1918, Arthur Stoll isolated ergotamine from ergot; the substance was eventually used to treat migraine and headaches and was introduced under the trade name Gynergen in 1921.{{Cite journal |title=50 years since the discovery of bromocriptine |url=https://academic.oup.com/ejendo/article-abstract/179/2/R69/6655383 |access-date=2023-07-05 |journal=European Journal of Endocrinology |date=August 2018 |volume=179 |issue=2 |pages=R69–R75 |doi=10.1530/EJE-18-0378 |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123516/https://academic.oup.com/ejendo/article-abstract/179/2/R69/6655383 |url-status=live |last1=Michael Besser |first1=G. |last2=Pfeiffer |first2=Ronald F. |last3=Thorner |first3=Michael O. |pmid=29752299 }}

In 1938 Albert Hofmann produced the synthetic substance lysergic acid diethylamide, better known as LSD. The psychoactive properties of this preparation were nevertheless not discovered until 1943, when Hofmann ingested a small amount by accident.{{Cite web |title=LSD - My Problem Child |url=http://www.psychedelic-library.org/child.htm |access-date=2023-07-05 |website=www.psychedelic-library.org |archive-date=2017-12-15 |archive-url=https://web.archive.org/web/20171215043651/http://www.psychedelic-library.org/child.htm |url-status=dead }}{{Cite web |title=Patent US2438259 - D-lysergic acid diethyl amide |url=https://patents.google.com/patent/US2438259 |url-status=live |archive-url=https://web.archive.org/web/20160609005436/http://www.google.com/patents/US2438259 |archive-date=9 June 2016 |access-date=11 November 2016 |website=google.com}} From 1947 to the mid-60s, LSD was sold by Sandoz under the name Delysid.{{Cite web |date=2013-10-20 |title=Albert Hofmann, 102, Invented LSD - The New York Sun |url=http://www.nysun.com/obituaries/albert-hofmann-102-invented-lsd/75591/ |access-date=2023-07-05 |archive-url=https://web.archive.org/web/20131020203430/http://www.nysun.com/obituaries/albert-hofmann-102-invented-lsd/75591/ |archive-date=2013-10-20}} It was marketed as a treatment for a wide variety of mental ailments, ranging from alcoholism to sexual deviancy. Sandoz suggested in its marketing literature that psychiatrists take LSD themselves,{{Cite web |title=Albert Hofmann: LSD - My Problem Child: Use of LSD in Psychiatry |url=http://www.flashback.se/archive/my_problem_child/chapter4.html#2 |url-status=dead |archive-url=https://web.archive.org/web/20060707201805/http://www.flashback.se/archive/my_problem_child/chapter4.html |archive-date=2006-07-07 |access-date=2012-01-16 |publisher=Flashback.se}} to gain a better subjective understanding of the schizophrenic experience, and many did exactly that and so did other scientific researchers. The Sandoz product received mass publicity as early as 1954, in a Time magazine feature.{{Cite news |date=28 June 1954 |title=Medicine: Dream Stuff |magazine=Time |url=http://www.time.com/time/magazine/article/0,9171,860898,00.html |url-status=dead |archive-url=https://web.archive.org/web/20130827000524/http://www.time.com/time/magazine/article/0%2C9171%2C860898%2C00.html |archive-date=27 August 2013 |df=dmy-all}} Research on LSD peaked in the 1950s and early 1960s. The CIA purchased quantities of LSD from Sandoz for use in its illegal human experimentation program known as MKUltra.{{cite web |date=5 August 1976 |title=CIA considered big LSD purchase |url=https://www.nytimes.com/1976/08/05/archives/cia-considered-big-lsd-purchase-agency-data-disclose-1953-idea-to.html |access-date=25 May 2022 |website=The New York Times |archive-date=24 May 2022 |archive-url=https://web.archive.org/web/20220524210752/https://www.nytimes.com/1976/08/05/archives/cia-considered-big-lsd-purchase-agency-data-disclose-1953-idea-to.html |url-status=live }} Sandoz withdrew the drug from the market in 1965. The drug became a cultural novelty of the 1960s after psychologist Timothy Leary at Harvard University began to promote its use for recreational and spiritual experiences among the general public.{{Cite magazine |last=Miller |first=Greg |title=Timothy Leary's Transformation From Scientist to Psychedelic Celebrity |language=en-US |magazine=Wired |url=https://www.wired.com/2013/10/timothy-leary-archives/ |access-date=2023-07-05 |issn=1059-1028 |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123516/https://www.wired.com/2013/10/timothy-leary-archives/ |url-status=live }}

In 1939, Kern & Sandoz became Sandoz Ltd., a name it operated under for nearly sixty years.{{Cite web |last=Pageflow |title=Swiss pharma reckons with its past, present and future |url=https://stories.swissinfo.ch/history-of-swiss-pharma |access-date=2023-07-05 |website=swissinfo.ch |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705072351/https://stories.swissinfo.ch/history-of-swiss-pharma |url-status=live }}

In 1963, Sandoz acquired Biochemie GmbH, which was producing and supplying scarce, urgently needed acid-resistant penicillin.

In 1967, Sandoz merged with Wander AG and diversified into the dietetics business with Ovomaltine and Isostar.{{Cite web |title=Wander |url=https://hls-dhs-dss.ch/articles/041974/2014-12-27/ |access-date=2023-07-05 |website=hls-dhs-dss.ch |language=de |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123515/https://hls-dhs-dss.ch/articles/041974/2014-12-27/ |url-status=live }}

In 1972, Sandoz acquired Delmark, Wasabröd, Wasa, the Swedish crisp bread producer Wasa in 1982.{{Cite web |title=Biographie Sandoz |url=https://www.musicme.com/Sandoz/biographie/ |access-date=2023-07-05 |website=musicMe}}

In 1986, Velsicol Chemical Corporation acquired the agrochemicals division of Sandoz.{{Cite news |last= |date=1986-01-29 |title=Sandoz Agreement |language=en-US |work=The New York Times |url=https://www.nytimes.com/1986/01/29/business/sandoz-agreement.html |access-date=2023-07-05 |issn=0362-4331 |archive-date=2023-07-04 |archive-url=https://web.archive.org/web/20230704110635/https://www.nytimes.com/1986/01/29/business/sandoz-agreement.html |url-status=live }}

In 1994, Sandoz bought Gerber Products Company, expanding its research into biopharmacueticals.{{Cite news |last= |date=1994-08-26 |title=COMPANY NEWS; SANDOZ COMPLETES $3.7 BILLION ACQUISITION OF GERBER |language=en-US |work=The New York Times |url=https://www.nytimes.com/1994/08/26/business/company-news-sandoz-completes-3.7-billion-acquisition-of-gerber.html |access-date=2023-07-05 |issn=0362-4331 |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705072352/https://www.nytimes.com/1994/08/26/business/company-news-sandoz-completes-3.7-billion-acquisition-of-gerber.html |url-status=live }}{{Cite news |last=Tagliabue |first=John |date=1995-07-11 |title=Sandoz Sharpens Its Focus on the Drugs of Tomorrow |language=en-US |work=The New York Times |url=https://www.nytimes.com/1995/07/11/business/sandoz-sharpens-its-focus-on-the-drugs-of-tomorrow.html |access-date=2023-07-05 |issn=0362-4331 |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705072349/https://www.nytimes.com/1995/07/11/business/sandoz-sharpens-its-focus-on-the-drugs-of-tomorrow.html |url-status=live }}

In 1995, the specialty chemicals division became an independent company under the name Clariant, based in Muttenz.Anna Bálint: Clariant clareant. Die Anfänge eines Spezialitätenchemiekonzerns. Campus Verlag, Frankfurt am Main/New York 2011, ISBN 978-3-593-39375-9.Anna Bálint: Clariant clareant. The beginnings of a specialty chemicals company. Campus Verlag, Frankfurt am Main/New York 2012, ISBN 978-3-593-39374-2.{{Cite news |last= |first= |date=1995-03-24 |title=INTERNATIONAL BUSINESS; Sandoz to Sell Its Chemical Unit To Focus on Pharmaceuticals |language=en-US |work=The New York Times |url=https://www.nytimes.com/1995/03/24/business/international-business-sandoz-sell-its-chemical-unit-focus-pharmaceuticals.html |access-date=2023-07-05 |issn=0362-4331 |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705072356/https://www.nytimes.com/1995/03/24/business/international-business-sandoz-sell-its-chemical-unit-focus-pharmaceuticals.html |url-status=live }}

On December 20, 1996, the merger of Sandoz and Ciba-Geigy led to the creation of Novartis. The Sandoz brand name was then only used in the pharmaceutical business for over-the-counter medicines.{{Cite web |date=2014-03-17 |title=This month in 1996: Ciba-Geigy and Sandoz merge |url=https://www.pmlive.com/pharma_news/this_month_in_1996_ciba-geigy_and_sandoz_merge_553502 |access-date=2023-07-05 |website=PMLive |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705072350/https://www.pmlive.com/pharma_news/this_month_in_1996_ciba-geigy_and_sandoz_merge_553502 |url-status=live }}

The former company name Sandoz was reactivated in May 2003 with the merger of the globally differently named generics companies of the parent company Novartis under the uniform brand name Sandoz. In addition to the name, the company logo used before the merger was also adopted.

In 2002, Sandoz acquired Lek Pharmaceuticals d.d., Slovenia's largest pharmaceutical company.{{Cite web |title=Novartis successfully completes friendly public offer for Lek, with more than 99% of shares tendered |url=https://www.lek.si/en/media-room/press-releases/257/novartis-successfully-completes-friendly-public-offer-for-lek-with-more-than-99-of-shares-tendered/ |access-date=2023-07-05 |website=www.lek.si |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123520/https://lek.si/en/media-room/press-releases/257/novartis-successfully-completes-friendly-public-offer-for-lek-with-more-than-99-of-shares-tendered/ |url-status=live }}

In 2003, Novartis united its global generics businesses under a single global brand, reestablishing the name Sandoz as a division of Novartis.{{Cite web |title=Novartis Generics to be rebranded as Sandoz |url=http://test.pharmabiz.com/news/novartis-generics-to-be-rebranded-as-sandoz-15681 |access-date=2023-07-05 |website=test.pharmabiz.com |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705072350/http://test.pharmabiz.com/news/novartis-generics-to-be-rebranded-as-sandoz-15681 |url-status=live }} The Amifarma S.L. production plant in Palafolls, located near Barcelona, Spain was also acquired.

In February 2005, Sandoz acquired over Hexal AG and Eon Labs. The integration into Sandoz created the second largest generics group in the world and the largest on the German market with annual sales of 7.6 billion US dollars (2008) and over 23,000 employees in 130 countries. The headquarters have been in Holzkirchen since 2005. Sandoz's Swiss administrative headquarters are in Rotkreuz ZG in the municipality of Risch in the canton of Zug.[http://www.zugerzeitung.ch/nachrichten/zentralschweiz/zug/Novartis-buendelt-Geschaeftseinheiten-in-Rotkreuz;art93,268968 Novartis bündelt Geschäftseinheiten in Rotkreuz.] {{Webarchive|url=https://web.archive.org/web/20230409113122/https://www.zugerzeitung.ch/nachrichten/zentralschweiz/zug/Novartis-buendelt-Geschaeftseinheiten-in-Rotkreuz;art93,268968 |date=2023-04-09 }} Zuger Zeitung, 14 June 2013.

In 2006, Omnitrope, a recombinant human growth hormone, was approved by the European Medicines Agency (EMA) and also became the first biosimilar to receive approval from the FDA.{{Cite web |title=Drug Approval Package: Omnitrope (Somatropia [rDNA origin]) NDA #021426 |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021426s000TOC.cfm |access-date=2023-07-05 |website=www.accessdata.fda.gov |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123516/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021426s000TOC.cfm |url-status=live }}

In 2007, the first complex biosimilar, Binocrit was approved in the EU.{{Cite web |last=EMA |date=2018-09-17 |title=Binocrit |url=https://www.ema.europa.eu/en/medicines/human/EPAR/binocrit |access-date=2023-07-05 |website=European Medicines Agency |language=en |archive-date=2019-12-30 |archive-url=https://web.archive.org/web/20191230161254/https://www.ema.europa.eu/en/medicines/human/EPAR/binocrit |url-status=live }}

In 2009, Sandoz acquired EBEWE Pharma's specialty generic injectables division and in 2010, acquired Oriel Therapeutics.{{Cite web |date=2010-04-19 |title=Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD |url=https://www.myscience.ch/en/news/wire/sandoz_acquire_oriel_therapeutics_gaining_rights_portfolio_respiratory_products_targeting_asthma-novartis |access-date=2023-07-05 |website=www.myscience.ch |language=it |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123517/https://www.myscience.ch/en/news/wire/sandoz_acquire_oriel_therapeutics_gaining_rights_portfolio_respiratory_products_targeting_asthma-novartis |url-status=live }}{{Cite web |title=Sandoz Completes Acquisition Of EBEWE Pharma |url=https://www.pharmaceuticalonline.com/doc/sandoz-completes-acquisition-of-ebewe-pharma-0001 |access-date=2023-07-05 |website=www.pharmaceuticalonline.com |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123516/https://www.pharmaceuticalonline.com/doc/sandoz-completes-acquisition-of-ebewe-pharma-0001 |url-status=live }}

In 2012, Sandoz acquired Fougera Pharmaceuticals, entering the generic (topical) dermatology business.{{Cite press release |last=Sandoz |title=Sandoz completes acquisition of Fougera Pharmaceuticals, positioning Sandoz as #1 in generic dermatology globally |url=https://www.prnewswire.com/news-releases/sandoz-completes-acquisition-of-fougera-pharmaceuticals-positioning-sandoz-as-1-in-generic-dermatology-globally-163374076.html |access-date=2023-07-05 |website=www.prnewswire.com |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123515/https://www.prnewswire.com/news-releases/sandoz-completes-acquisition-of-fougera-pharmaceuticals-positioning-sandoz-as-1-in-generic-dermatology-globally-163374076.html |url-status=live }}

In November 2018, it was announced that Novartis would convert Sandoz into an independent entity over the next two years.{{Cite web |title=Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo |url=https://www.sandoz.com/news/media-releases/novartis-divest-sandoz-us-dermatology-business-and-generic-us-oral-solids-portfolio-aurobindo |access-date=2023-07-05 |website=Sandoz |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123516/https://www.sandoz.com/news/media-releases/novartis-divest-sandoz-us-dermatology-business-and-generic-us-oral-solids-portfolio-aurobindo |url-status=live }} In March 2019, it was announced that CEO Richard Francis had resigned for personal reasons and that Francesco Balestrieri, Sandoz's European head, had taken over management ad interim.{{Cite news |date=2019-03-14 |title=Novartis generics boss quits amid conjecture over business's future |language=en |work=Reuters |url=https://www.reuters.com/article/us-novartis-sandoz-idUSKCN1QV0LR |access-date=2023-07-05 |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705080100/https://www.reuters.com/article/us-novartis-sandoz-idUSKCN1QV0LR |url-status=live }}{{Cite web |title=Novartis Poaches GSK Veteran as New Sandoz CEO |url=https://www.biospace.com/article/novartis-poaches-gsk-veteran-as-new-sandoz-ceo/ |access-date=2023-07-05 |website=BioSpace |date=24 April 2019 |language=en-US |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705080101/https://www.biospace.com/article/novartis-poaches-gsk-veteran-as-new-sandoz-ceo/ |url-status=live }} Richard Saynor was appointed as CEO later in 2019.

In August 2022, Novartis said the spin-off of Sandoz into a standalone company would be completed by the end of 2023.{{Cite web |last=Keystone-SDA/jdp |date=2022-08-25 |title=Novartis plans to spin off generics division Sandoz |url=https://www.swissinfo.ch/eng/business/novartis-plans-to-spin-off-generics-division-sandoz/47851706 |access-date=2023-07-05 |website=SWI swissinfo.ch |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123516/https://www.swissinfo.ch/eng/business/novartis-plans-to-spin-off-generics-division-sandoz/47851706 |url-status=live }} As part of the spin-off, Sandoz announced in June 2023 it would move its headquarters from Holzkirchen, Germany to Basel, Switzerland.{{Cite news |title=Sandoz to move headquarters to Basel, Switzerland |url=https://www.europeanpharmaceuticalreview.com/news/183184/sandoz-to-move-headquarters-to-basel-switzerland/ |access-date=2023-07-05 |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705080106/https://www.europeanpharmaceuticalreview.com/news/183184/sandoz-to-move-headquarters-to-basel-switzerland/ |url-status=live }}

In July 2023, Sandoz launched a biosimilar version of AbbVie Inc's Humira, under the label, Hyrimoz.{{Cite news |last= |date=2023-07-01 |title=Sandoz launches rival version of AbbVie's arthritis drug Humira |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-launches-rival-version-abbvies-arthritis-drug-humira-2023-07-01/ |access-date=2023-07-05 |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705123515/https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-launches-rival-version-abbvies-arthritis-drug-humira-2023-07-01/ |url-status=live }}

In September 2023, Novartis announced that the spin-off had been approved by its shareholders and that it would be completed by the next month, resulting in Novartis shareholders receiving one Sandoz share for every five Novartis shares.{{Cite news |last=Burger |first=Ludwig |date=15 September 2023 |title=Novartis shareholders vote in favour of Sandoz spin-off |url=https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-shareholders-vote-favour-sandoz-spin-off-2023-09-15/ |access-date=18 September 2023 |work=Reuters |language=en |archive-date=26 September 2023 |archive-url=https://web.archive.org/web/20230926085615/https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-shareholders-vote-favour-sandoz-spin-off-2023-09-15/ |url-status=live }}{{Cite news |last=Kuchler |first=Hannah |date=2023-08-18 |title=Novartis plans to spin off Sandoz in October |url=https://www.ft.com/content/85a15324-2569-4ff3-97c5-8e6d528eb0d1 |work=Financial Times |access-date=2023-09-19 |archive-date=2023-10-04 |archive-url=https://web.archive.org/web/20231004050617/https://www.ft.com/content/85a15324-2569-4ff3-97c5-8e6d528eb0d1 |url-status=live }} Sandoz was listed on the SIX Swiss Exchange with a market capitalization between $18 billion and $25bn.{{Cite news |title=Sandoz to initially join Swiss mid-cap index after listing - SIX exchange |url=https://www.reuters.com/article/novartis-sandoz-listing/sandoz-to-initially-join-swiss-mid-cap-index-after-listing-six-exchange-idUKL8N3AQ0VL |date=2023-09-13 |work=Reuters |access-date=2023-09-19 |archive-date=2023-10-04 |archive-url=https://web.archive.org/web/20231004050617/https://www.reuters.com/article/novartis-sandoz-listing/sandoz-to-initially-join-swiss-mid-cap-index-after-listing-six-exchange-idUKL8N3AQ0VL |url-status=live }}

On October 4, 2023, Novartis completed the spin-off of Sandoz as a stand-alone company.{{Cite web |last1=Veyet |first1=Tristan |last2=Illien |first2=Noele |date=2023-10-04 |title=Novartis completes Sandoz spinoff |url=https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-completes-sandoz-spinoff-2023-10-04/ |access-date=2023-10-04 |work=Reuters |language=en |archive-date=2023-10-04 |archive-url=https://web.archive.org/web/20231004123809/https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-completes-sandoz-spinoff-2023-10-04/ |url-status=live }}

The B2B business unit of Sandoz, dedicated to supplying active pharmaceutical ingredients (APIs), out-licensing of Finished Dosage Forms (FDFs), and Contract Manufacturing Organization (CMO) services, continues to operate from its global headquarters in Kufstein, Austria, which was inaugurated in June 2023. The unit supplies over 200 customers in 77 countries and delivers around 800 million treatments per year.{{Cite web |title=Wir machen Kufstein bunter: B2B, eine globale Geschäftseinheit von Sandoz… {{!}} Michael Kocher {{!}} 15 comments |url=https://www.linkedin.com/posts/michael-kocher-191863a_wir-machen-kufstein-bunter-b2b-eine-globale-activity-7074678892682182656-b0bH/?originalSubdomain=de |access-date=2025-04-28 |website=de.linkedin.com |language=en}}

In January 2024, Sandoz announced it would acquire biosimilar drug for vision Cimerli For $170 million from Coherus BioSciences.{{cite web |title=Sandoz to buy eye drug Cimerli in $170 million deal |url=https://www.reuters.com/markets/deals/sandoz-buy-eye-drug-cimerli-170-million-deal-2024-01-22/ |work=Reuters |access-date=22 January 2024 |date=22 January 2024}} The acquisition was completed in March 2024.{{Cite web |date=2024-03-04 |title=Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market |url=https://finance.yahoo.com/news/sandoz-acquires-cimerli-business-coherus-060000004.html |access-date=2024-03-04 |website=Yahoo Finance |language=en-US |archive-date=2024-03-04 |archive-url=https://web.archive.org/web/20240304201140/https://finance.yahoo.com/news/sandoz-acquires-cimerli-business-coherus-060000004.html |url-status=live }}

In February 2024, Sandoz US and its subsidiary Fougera Pharmaceuticals Inc. - indirect subsidiaries of Sandoz Group AG reached a USD 265 million settlement agreement in the US related to a generics direct purchaser class action lawsuit.{{Cite web |title=Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs |url=https://www.sandoz.com/sandoz-us-subsidiaries-resolve-generic-drug-antitrust-class-action-litigation-direct-purchaser/ |access-date=2024-02-29 |website=www.sandoz.com |archive-date=2024-02-29 |archive-url=https://web.archive.org/web/20240229085709/https://www.sandoz.com/sandoz-us-subsidiaries-resolve-generic-drug-antitrust-class-action-litigation-direct-purchaser/ |url-status=live }}

In April 2024, Sandoz reached an agreement with Amgen to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars.{{Cite web |author=A. O. L. Staff |date=2024-04-30 |title=Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab |url=https://www.aol.com/sandoz-settles-patent-dispute-amgen-175459794.html |access-date=2024-04-30 |website=www.aol.com |language=en-US}}

In November 2024, Sandoz inaugurated the new headquarters in Basel, Switzerland.{{Cite web |title=Sandoz celebrates the inauguration of new global headquarters in Basel |url=https://www.sandoz.com/sandoz-celebrates-inauguration-new-global-headquarters-basel/ |access-date=2024-11-19 |website=www.sandoz.com}}{{Cite web |title=Sandoz eröffnet neuen globalen Hauptsitz in Basel |url=https://www.hkbb.ch/de/dienstleistungen/mitgliedschaft/Sandoz_eroeffnet_neuen_globalen_Hauptsitz_in_Basel.php |access-date=2024-11-19 |website=Handelskammer beider Basel |language=de}}

{{main article|Sandoz chemical spill}}

On November 1, 1986, a major fire broke out in a warehouse containing {{convert|1,350|t|lb}} of chemicals in what was then Sandoz in Schweizerhalle. The thick smoke, the stench and the unknown composition of the combustion gases caused the authorities in the neighboring communities to alert the population early in the morning with a general siren alarm and a curfew of several hours was imposed. No people suffered acute harm, with the exception of three people with pre-existing asthma who required hospitalization. However, the toxins found their way into the Rhine via the extinguishing water, where they caused a large number of fish to die off.{{Cite web |title=Sandoz Chemical Disaster |url=https://www.environmentandsociety.org/tools/keywords/sandoz-chemical-disaster |access-date=2023-07-05 |website=Environment & Society Portal |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705081851/https://www.environmentandsociety.org/tools/keywords/sandoz-chemical-disaster |url-status=live }}

On November 11, 1986, the analysis of water samples proved that at the same time as the Rhine was being polluted by the contaminated extinguishing water from the Sandoz area, 400 kg of atrazine, a herbicide, had been discharged into the Rhine from the neighboring chemical company Ciba-Geigy.Walter Reinhard: [http://flussgebiete.hessen.de/fileadmin/dokumente/4_oeffentlichkeitsbeteiligung/111123reinhard.pdf 25 Jahre SANDOZ-Katastrophe am Rhein – Auswirkungen auf den Gewässerschutz] {{Webarchive|url=https://web.archive.org/web/20230605231034/https://flussgebiete.hessen.de/fileadmin/dokumente/4_oeffentlichkeitsbeteiligung/111123reinhard.pdf |date=2023-06-05 }}, 23 November 2011, retrieved 31 October 2016.{{citation |author= |title=Wir sollten aufwachen und überlegen |url=http://www.spiegel.de/spiegel/print/d-13521501.html |work=Der Spiegel |volume= |issue=47 |pages= |year=1986 |series=17 November 1986 |quote= |access-date=5 July 2023 |archive-date=10 December 2018 |archive-url=https://web.archive.org/web/20181210154602/http://www.spiegel.de/spiegel/print/d-13521501.html |url-status=live }}

The official investigation report came to the conclusion (only "on the basis of theoretical considerations") that when pallets were packed with Prussian blue, incorrect handling of a hot air blower led to a hot spot, which could be the cause. Subsequent trials, however, resulted in no conviction. The plant now belongs to Clariant.{{Cite web |last=agencies |first=swissinfo ch and |date=2016-11-01 |title=Chemical disaster still burns in Swiss memory |url=https://www.swissinfo.ch/eng/sci-tech/schweizerhalle-fire_chemical-disaster-still-burns-in-swiss-memory/42559954 |access-date=2023-07-05 |website=SWI swissinfo.ch |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705081843/https://www.swissinfo.ch/eng/sci-tech/schweizerhalle-fire_chemical-disaster-still-burns-in-swiss-memory/42559954 |url-status=live }}

To this day, the landfill left after the fire continues to pollute the groundwater in Muttenz and is actively monitored by Novartis, as the legal successor to Sandoz, and the environmental authorities of the Canton of Basel-Landschaft.Martin Forter: Falsches Spiel. Die Umweltsünden der Basler Chemie vor und nach "Schweizerhalle". Chronos Verl., Zürich, 2010. ISBN 978-3-0340-1007-8{{Cite web |title=Sandoz Chemical Spill |url=https://prezi.com/p/kr1flxnfh9zf/sandoz-chemical-spill/ |access-date=2023-07-05 |website=prezi.com |language=en |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705081842/https://prezi.com/p/kr1flxnfh9zf/sandoz-chemical-spill/ |url-status=live }}

To commemorate the spill, there is a plastic market table by Bettina Eichin in the cloister of Basel Munster.{{Cite web |last= |first= |title=Münster-Kreuzgang soll endgültige Heimat der Eichin-Tische werden |url=https://www.onlinereports.ch/Kultur.111+M5245e650d3a.0.html |access-date=2023-07-05 |website=www.onlinereports.ch |language=de |archive-date=2023-07-05 |archive-url=https://web.archive.org/web/20230705081842/https://www.onlinereports.ch/Kultur.111+M5245e650d3a.0.html |url-status=live }}

• Ernst Brandl: Zur Entdeckungsgeschichte des Penicillin V in Kundl (Tirol). In: Veröffentlichungen des Tiroler Landesmuseums Ferdinandeum. Band 71, Innsbruck 1991, S. 5–16 (Geschichte der Bio Chemie in Kundl, [https://www.zobodat.at/pdf/VeroeffFerd_71_0005-0016.pdf zobodat.at]).

• Pharmaceutical industry in Switzerland

{{reflist}}

{{Commons category|Sandoz}}

• {{Official website|https://www.sandoz.com/}}

{{Pharmaceutical companies of Switzerland}}

{{Portal bar|Companies|Switzerland|Germany}}

{{SMI MID companies}}

{{Authority control}}

{{authority control|qid=Q528468}}

{{DEFAULTSORT:Sandoz}}

Category:1996 mergers and acquisitions

Category:Biotechnology companies of Switzerland

Category:Manufacturing companies based in Basel

Category:Companies listed on the SIX Swiss Exchange

Category:Corporate spin-offs

Category:Life sciences industry

Category:Pharmaceutical companies of Switzerland

Category:Swiss brands

Category:Zug